Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Abstract

The present invention is directed to the dihydrogen phosphate salt of 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

Description

Dihydrogen Phosphate Salt of Prostaglandin D2 Receptor Antagonist field of invention Large-scale production of pharmaceutical compositions can pose many challenges to chemists and chemical engineers. While many of these challenges involve the handling of large quantities of reagents and the control of large-scale reactions, handling of the final product presents special challenges related to the nature of the final active product itself. Such a product must not only be high yielding, stable and easy to isolate, but it must have properties suitable for the type of pharmaceutical formulation that may ultimately be used. The stability of active ingredients of pharmaceutical formulations must be considered at every step of the production process, including synthesis, isolation, bulk storage, drug formulation and long-term formulation. Each of these steps can be affected by various environmental conditions such as temperature and humidity. The pharmaceutically active substance ...

AI Technical Summary

Problems solved by technology

However, the '732 publication does not specifically disclose that 2-(3-{6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidin-4-yl}phenyl)- Dihydrogen Phosphate of 2-Methylpropionic Acid

Images